Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 46 (9) , 1251-1258
Abstract
For successful in vitro-to-in vivo extrapolation (IVIVE) of hepatic drug uptake and DDI, it is important to characterize the kinetic properties of the individual transporters involved, their fraction (ft) contribution to hepatic uptake, and their selective inhibitors. Here, we characterized the in vitro transport kinetics of two model drugs, rosuvastatin (RSV) and olmesartan acid (OLM), by rat hepatic organic anion transporting polypeptides (Oatp1a1, 1a4 and 1b2) and identified selective inhibitors of these transporters. [3H]-RSV was transported by Oatp1a1, 1a4 and 1b2, and their Km values were estimated to be 9.61, 67.2, and 28.1 μM, respectively. In contrast, [3H]-OLM was transported by only Oatp1b2 (Km: 72.8 μM). Digoxin (IC50: 0.107 μM) and rifamycin SV (IC50: 0.140 and 0.088 μM for RSV and OLM, respectively) were potent and selective inhibitors of Oatp1a4 and 1b2, respectively, whilst glyburide (100 μM) completely inhibited all three rat hepatic Oatps. These inhibitors can therefore be used alone and in combination to determine the contribution of each Oatp to hepatic influx. In addition, the magnitude of in vivo inhibition of sinusoidal uptake clearance of RSV by rifampin was well predicted using rifampin IC50 profiles for each Oatps and RSV ft by each Oatp. This is the first report to: 1) detail the transport kinetics of RSV and OLM by rat hepatic Oatps; 2) identify selective inhibitor concentrations of rat Oatps; 3) demonstrate successful prediction of the magnitude of transporter-mediated in vivo DDI from IC50 profiles of an inhibitor and ft of a drug by each transporter.Keywords
This publication has 16 references indexed in Scilit:
- Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative ProteomicsDrug Metabolism and Disposition, 2018
- Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are InvolvedClinical Pharmacokinetics, 2014
- PET Imaging of Oatp-Mediated Hepatobiliary Transport of [11C] Rosuvastatin in the RatMolecular Pharmaceutics, 2014
- Predicting the Outer Boundaries of P-glycoprotein (P-gp)-Based Drug Interactions at the Human Blood–Brain Barrier Based on Rat StudiesMolecular Pharmaceutics, 2014
- P-Glycoprotein-Based Loperamide–Cyclosporine Drug Interaction at the Rat Blood–Brain Barrier: Prediction fromIn VitroStudies and Extrapolation to HumansMolecular Pharmaceutics, 2012
- The Role of the Equilibrative Nucleoside Transporter 1 (ENT1) in Transport and Metabolism of Ribavirin by Human and Wild-Type or Ent1(-/-) Mouse ErythrocytesThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and PharmacogeneticsGastroenterology, 2006
- Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liverHepatology Research, 2003
- Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2Hepatology, 2000
- Allosterism and Na++-d-glucose cotransport kinetics in rabbit jejunal vesicles: Compatibility with mixed positive and negative cooperativities in a homo- dimeric or tetrameric structure and experimental evidence for only one transport protein involvedThe Journal of Membrane Biology, 1993